These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 37289463)
1. Accuracy of Artificial Intelligence in Estimating Best-Corrected Visual Acuity From Fundus Photographs in Eyes With Diabetic Macular Edema. Paul W; Burlina P; Mocharla R; Joshi N; Li Z; Gu S; Nanegrungsunk O; Lin K; Bressler SB; Cai CX; Kong J; Liu TYA; Moini H; Du W; Amer F; Chu K; Vitti R; Sepehrband F; Bressler NM JAMA Ophthalmol; 2023 Jul; 141(7):677-685. PubMed ID: 37289463 [TBL] [Abstract][Full Text] [Related]
2. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial. Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK; JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907 [TBL] [Abstract][Full Text] [Related]
3. Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial. Roberts PK; Vogl WD; Gerendas BS; Glassman AR; Bogunovic H; Jampol LM; Schmidt-Erfurth UM JAMA Ophthalmol; 2020 Sep; 138(9):945-953. PubMed ID: 32722799 [TBL] [Abstract][Full Text] [Related]
4. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study. Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S; Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168 [TBL] [Abstract][Full Text] [Related]
5. Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema. Moshfeghi AA; Shapiro H; Lemmon LA; Gune S Ophthalmol Retina; 2018 Feb; 2(2):86-90. PubMed ID: 31047350 [TBL] [Abstract][Full Text] [Related]
6. Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial. Maturi RK; Glassman AR; Josic K; Antoszyk AN; Blodi BA; Jampol LM; Marcus DM; Martin DF; Melia M; Salehi-Had H; Stockdale CR; Punjabi OS; Sun JK; JAMA Ophthalmol; 2021 Jul; 139(7):701-712. PubMed ID: 33784735 [TBL] [Abstract][Full Text] [Related]
7. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program. Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658 [TBL] [Abstract][Full Text] [Related]
8. Diabetic Macular Edema and Diode Subthreshold Micropulse Laser: A Randomized Double-Masked Noninferiority Clinical Trial. Lois N; Campbell C; Waugh N; Azuara-Blanco A; Maredza M; Mistry H; McAuley D; Acharya N; Aslam TM; Bailey C; Chong V; Downey L; Eleftheriadis H; Fatum S; George S; Ghanchi F; Groppe M; Hamilton R; Menon G; Saad A; Sivaprasad S; Shiew M; Steel DH; Talks JS; Doherty P; McDowell C; Clarke M; Ophthalmology; 2023 Jan; 130(1):14-27. PubMed ID: 35973593 [TBL] [Abstract][Full Text] [Related]
9. Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. Gonzalez VH; Campbell J; Holekamp NM; Kiss S; Loewenstein A; Augustin AJ; Ma J; Ho AC; Patel V; Whitcup SM; Dugel PU Am J Ophthalmol; 2016 Dec; 172():72-79. PubMed ID: 27644589 [TBL] [Abstract][Full Text] [Related]
10. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. Baker CW; Glassman AR; Beaulieu WT; Antoszyk AN; Browning DJ; Chalam KV; Grover S; Jampol LM; Jhaveri CD; Melia M; Stockdale CR; Martin DF; Sun JK; JAMA; 2019 May; 321(19):1880-1894. PubMed ID: 31037289 [TBL] [Abstract][Full Text] [Related]
11. Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema. Sivaprasad S; Regnier SA; Fajnkuchen F; Wright J; Berger AR; Mitchell P; Larsen M Adv Ther; 2016 Apr; 33(4):597-609. PubMed ID: 26951552 [TBL] [Abstract][Full Text] [Related]
12. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808 [TBL] [Abstract][Full Text] [Related]
13. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Bahrami B; Hong T; Zhu M; Schlub TE; Chang A Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195 [TBL] [Abstract][Full Text] [Related]
14. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial. Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; Moll AC; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO; Ophthalmol Retina; 2020 Aug; 4(8):777-788. PubMed ID: 32362552 [TBL] [Abstract][Full Text] [Related]
15. Intravitreal aflibercept for diabetic macular edema. Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Snellen Visual Acuity Measurements in Retinal Clinical Practice to Electronic ETDRS Protocol Visual Acuity Assessment. Baker CW; Josic K; Maguire MG; Jampol LM; Martin DF; Rofagha S; Sun JK; Ophthalmology; 2023 May; 130(5):533-541. PubMed ID: 36521571 [TBL] [Abstract][Full Text] [Related]
17. Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti-Vascular Endothelial Growth Factor Therapy: A Post Hoc Analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) Trial. Gurudas S; Patrao N; Nicholson L; Sen P; Ramu J; Sivaprasad S; Hykin P JAMA Ophthalmol; 2022 Feb; 140(2):143-150. PubMed ID: 34989804 [TBL] [Abstract][Full Text] [Related]
18. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Do DV; Nguyen QD; Boyer D; Schmidt-Erfurth U; Brown DM; Vitti R; Berliner AJ; Gao B; Zeitz O; Ruckert R; Schmelter T; Sandbrink R; Heier JS; Ophthalmology; 2012 Aug; 119(8):1658-65. PubMed ID: 22537617 [TBL] [Abstract][Full Text] [Related]
19. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study. Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J; Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052 [TBL] [Abstract][Full Text] [Related]
20. Real-World Outcomes after 36-Month Treatment with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema (BOREAL-DME). Massin P; Creuzot-Garcher C; Kodjikian L; Girmens JF; Delcourt C; Fajnkuchen F; Glacet-Bernard A; Guillausseau PJ; Guthux F; Blin P; Grelaud A Ophthalmic Res; 2021; 64(4):577-586. PubMed ID: 32932257 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]